Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval
Bionoid Pharma (OTC:BINP) has received approval from Delaware for its name change to AI Maverick Intel, effective April 30, 2025. The company has initiated the FINRA process to update its name and trading symbol on OTC Markets. This rebranding reflects the company's strategic pivot towards leveraging artificial intelligence for acquiring and growing technology-driven businesses, particularly in AI, biotech, and digital health sectors.
Bionoid Pharma (OTC:BINP) ha ottenuto l'approvazione dal Delaware per il cambio di nome in AI Maverick Intel, con efficacia dal 30 aprile 2025. L'azienda ha avviato la procedura FINRA per aggiornare il nome e il simbolo di negoziazione sui mercati OTC. Questo rebranding riflette la nuova strategia aziendale focalizzata sull'utilizzo dell'intelligenza artificiale per acquisire e sviluppare imprese tecnologiche, in particolare nei settori AI, biotecnologie e salute digitale.
Bionoid Pharma (OTC:BINP) ha recibido la aprobación de Delaware para cambiar su nombre a AI Maverick Intel, con vigencia a partir del 30 de abril de 2025. La empresa ha iniciado el proceso FINRA para actualizar su nombre y símbolo de cotización en los mercados OTC. Este cambio de marca refleja el giro estratégico de la compañía hacia el aprovechamiento de la inteligencia artificial para adquirir y hacer crecer negocios tecnológicos, especialmente en los sectores de IA, biotecnología y salud digital.
Bionoid Pharma (OTC:BINP)가 2025년 4월 30일부터 효력이 발생하는 AI Maverick Intel로의 사명 변경을 델라웨어에서 승인받았습니다. 회사는 OTC 시장에서 이름과 거래 심볼을 업데이트하기 위해 FINRA 절차를 시작했습니다. 이번 리브랜딩은 인공지능을 활용해 기술 중심 사업, 특히 AI, 생명공학, 디지털 헬스 분야의 인수 및 성장을 추진하는 전략적 전환을 반영합니다.
Bionoid Pharma (OTC:BINP) a obtenu l'approbation du Delaware pour changer son nom en AI Maverick Intel, à compter du 30 avril 2025. La société a lancé la procédure FINRA afin de mettre à jour son nom et son symbole de cotation sur les marchés OTC. Ce rebranding reflète l'orientation stratégique de l'entreprise vers l'exploitation de l'intelligence artificielle pour acquérir et développer des entreprises technologiques, notamment dans les secteurs de l'IA, des biotechnologies et de la santé numérique.
Bionoid Pharma (OTC:BINP) hat die Genehmigung des Bundesstaates Delaware für die Namensänderung zu AI Maverick Intel erhalten, die am 30. April 2025 wirksam wird. Das Unternehmen hat den FINRA-Prozess eingeleitet, um seinen Namen und sein Handelssymbol auf den OTC-Märkten zu aktualisieren. Dieses Rebranding spiegelt die strategische Neuausrichtung des Unternehmens wider, die darauf abzielt, künstliche Intelligenz zu nutzen, um technologiegetriebene Unternehmen, insbesondere in den Bereichen KI, Biotechnologie und digitale Gesundheit, zu erwerben und zu fördern.
- Strategic repositioning towards high-growth AI and technology sectors
- Potential for new business opportunities in AI, biotech, and digital health
- Significant shift from original pharmaceutical focus may create business uncertainty
- Pending FINRA approval adds regulatory uncertainty to the rebranding process
Company Has Initiated FINRA Process to Complete Rebranding and Ticker Update
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bionoid Pharma, Inc. (OTC PINK:BINP) ("Bionoid" or the "Company") is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company's formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets.
Subject to FINRA's approval, the name and symbol change will be reflected in market listings and all future communications. This step marks the continued execution of the Company's new strategic direction, which centers on leveraging artificial intelligence to acquire, integrate, and grow technology-driven businesses.
"This milestone moves us one step closer to fully implementing the AI Maverick vision," said Wayne Cockburn, CEO. "As we align our public identity with our operational focus, we're unlocking new opportunities to scale our platform and partner with innovators across AI, biotech, and digital health. Our shareholders can expect a bold, tech-forward approach to growth."
About AI Maverick Intel, Inc.
AI Maverick Intel, Inc. is a growth-oriented AI company focused on acquiring and enhancing revenue-generating businesses through its proprietary AI Maverick platform. The technology enables intelligent, two-way communication and data-driven engagement across healthcare, biotech, and other sectors. AI Maverick Intel aims to deliver long-term value through innovation, efficiency, and strategic partnerships.
Stay Connected:
Website | AI Maverick | OTC:BINP | X: @BionoidPharminc
Media Contact:
Wayne Cockburn, CEO
(905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: AI Maverick Intel, Inc.
View the original press release on ACCESS Newswire
FAQ
Why is Bionoid Pharma (BINP) changing its name to AI Maverick Intel?
When will BINP stock ticker change after the company name change?
What is the effective date of Bionoid Pharma's name change to AI Maverick Intel?
What sectors will AI Maverick Intel (formerly BINP) focus on?
